NJ Bio, Inc., took the global stage at the 14th Annual World ADC conference, shedding light on a prevalent challenge in the world of Antibody-Drug Conjugates (ADCs). The issue at hand: the replication of ideas (or as we term it the “copy-paste” approach) and a stagnation of innovation that has contributed to a high number of discontinued and clinically inactive ADCs.
Leveraging years of expertise in the field of bioconjugation and developing novel linker-payload technology, NJ Bio introduced a solution with potential to address this particular issue in ADC development. “siteDAR©,” a highly useful tool that seamlessly integrates the capabilities of BioNMR technology offering the potential to engineer innovative next-generation ADCs. BioNMR, a cutting-edge resource, yields high-order structures of ADCs, that has contributed greatly to source important data to create this advanced tool. The presentation’s key findings spotlighted the attributes of siteDAR©, which bears the potential to accelerate the development of successful ADCs through the innovation of novel payload-linkers.
For an in-depth exploration of NJ Bio’s findings, you can access the detailed slide deck and research findings.
